雄激素受体在乳腺癌中与超声、临床病理特征和临床结果的相关性。
Correlation of androgen receptor with ultrasound, clinicopathological features and clinical outcomes in breast cancer.
发表日期:2023 Mar 16
作者:
Xudong Zhang, Hao Cui, Nana Hu, Peng Han, Wei Fan, Panting Wang, Xiaoxuan Zuo, Dantong Zhao, He Huang, Shuo Li, Hanqing Kong, Fuhui Peng, Jiawei Tian, Lei Zhang
来源:
Insights into Imaging
摘要:
本研究旨在探讨雄激素受体(AR)表达与乳腺癌超声、临床病理特征和预后之间的关联。该回顾性研究共纳入了141名乳腺癌患者。采用免疫组织化学法分析AR表达情况。收集了104名患者的B模式、彩色多普勒和应变弹性成像图像,并获取了相应的超声特征。分析了不同AR状态下超声和临床病理特征的差异。通过长达90个月的随访获得患者的无进展生存期(PFS),然后分析AR对PFS的影响。随后,构建了一个预测AR状态的图表,使用C指数计算预测准确性。AR阳性表达(AR+)与更低的组织学分级(p=0.034)和更低的Ki-67水平(p=0.029)相关。三阴性乳腺癌(TNBC)的AR+概率最低(p<0.001)。AR+ 组大多数显示出不光滑的边缘(p<0.001)、后声影(p=0.002)和更高的弹性评分(p=0.022)。大多数具有AR+的肿瘤的回声形态在内皮A亚型中是异质性的(p=0.024)。AR+ 可以是总体乳腺癌(p<0.001)以及人表皮生长因子受体2(HER2)过表达和内皮B亚型乳腺癌(p=0.001和0.025)较好预后的标志。该预测图表具有相对可靠的表现,C指数为0.799。研究表明,AR表达与乳腺癌超声、临床病理特征和预后密切相关。©2023年作者。
This study aimed to explore whether there is an association between androgen receptor (AR) expression and ultrasound, clinicopathological features and prognosis of breast cancer.A total of 141 breast cancer patients were included in this retrospective study. AR expression was analyzed by immunohistochemistry. The images of B-mode, color Doppler and strain elastography from 104 patients were collected continuously, and the corresponding ultrasound characteristics were obtained. The differences in ultrasound and clinicopathological features in different AR status were analyzed. Progression-free survival (PFS) of patients was obtained through up to 90 months of follow-up; then, the effect of AR on PFS was analyzed. Subsequently, a nomogram was constructed to predict the AR status. The predictive accuracy was calculated using C-index.The positive expression of AR (AR +) was associated with lower histological grade (p = 0.034) and lower Ki-67 level (p = 0.029). Triple-negative breast cancer (TNBC) had the lowest probability of AR + (p < 0.001). The AR + group mostly showed unsmooth margin (p < 0.001), posterior acoustic shadowing (p = 0.002) and higher elasticity score (p = 0.022) on ultrasound. The echo pattern of most tumors with AR + was heterogeneous (p = 0.024) in Luminal A subtype. AR + could be a sign of a better prognosis in overall breast cancer (p < 0.001), as well as in human epidermal growth factor receptor 2 (HER2) overexpression and Luminal B subtypes (p = 0.001 and 0.025). The nomogram showed relatively reliable performance with a C-index of 0.799.Our research demonstrated that AR expression was closely related to ultrasound, clinicopathological features and prognosis of breast cancer.© 2023. The Author(s).